Document is current
Any future updates will be listed below
-
Authors
Seront, Emmanuel https://orcid.org/0000-0003-4807-7472
Froidure, Antoine https://orcid.org/0000-0001-7133-1788
Revencu, Nicole https://orcid.org/0000-0002-7120-4903
Dekeuleneer, Valerie https://orcid.org/0000-0003-1210-6112
Clapuyt, Philippe https://orcid.org/0000-0001-6942-765X
Dumitriu, Dana https://orcid.org/0000-0003-0749-9695
Vikkula, Miikka https://orcid.org/0000-0002-6236-338X
Boon, Laurence M. https://orcid.org/0000-0001-8273-3328
- License Information
-
More Information
Article History
Received: 20 April 2024
Accepted: 5 May 2024
First Online: 16 May 2024
Declarations
:
: The patient and his parent were provided with comprehensive information regarding sirolimus as outlined in the VASE trial protocol. They consented to participate in the trial by signing the informed consent forms. Additionally, the patient consented to receive detailed information about trametinib, either as a standalone treatment or in combination with sirolimus, before signing another informed consent form. The patient's treatment and follow-up were conducted in accordance with the CARE guidelines.
: Even if images are entirely unidentifiable, written inform consents from the patient and his parents were obtained for publication.
: The authors declare no competing interests.
